Following the successful conclusion of a $5.0 million private placement, Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) saw a notable spike in its share price on Wednesday, ending at $2.02, representing a dramatic jump of 71.19%. In line with Nasdaq’s market-based rules, Common Stock, Pre-Funded Warrants, and Series B Convertible Preferred Stock were all issued as part of the equity offering.
Equity Deal Details
The private placement comprised 6,355,214 Common Warrants, 3,573,130 shares of Series B Convertible Preferred Stock, and 2,382,084 shares of Common Stock (or Pre-Funded Warrants in substitute). While each Common Warrant has an exercise price of $1.00 and is valid for 60 months after the resale registration statement takes effect, the Pre-Funded Warrants are instantly exercisable at a symbolic price of $0.00001 per share.
Lixte got $4.0 million of the $5.0 million in gross proceeds from the deal, completed on July 2, 2025, upon closure. The remaining $1.0 million was due when the registration statement was activated. Lixte plans to allocate the net proceeds toward general corporate objectives and working capital.
Research Advances in Cancer Prevention
In parallel with its financial developments, Lixte has made notable progress on the research front. In order to determine if its flagship product, LB-100, can effectively target “initiated” cells—those that contain early cancer-related mutations—the business has started a pre-clinical research in partnership with the Netherlands Cancer Institute (NKI). This study complements Lixte’s ongoing clinical studies in colorectal and ovarian malignancies and introduces a new avenue for cancer prevention.
Early Trials Show Promise for LB-100
In Phase 1 studies, LB-100 has already shown encouraging safety results, including minimal toxicity and excellent tolerance. Additionally, it has been discovered that the chemical causes oncogenic signaling, which is detrimental to malignant cells. This feature makes LB-100 a potentially useful medication for early intervention as well as therapy of pre-malignant disorders resulting from age-related genetic alterations.
